{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:52:47Z","timestamp":1786373567043,"version":"build-2736575974"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:p>\n                    Among patients on dialysis, hypertension is highly prevalent and contributes to the high burden of cardiovascular morbidity and mortality. Strict volume control\n                    <jats:italic toggle=\"yes\">via<\/jats:italic>\n                    sodium restriction and probing of dry weight are first-line approaches for the treatment of hypertension in this population; however, antihypertensive drug therapy is often needed to control BP. Few trials compare head-to-head the superiority of one antihypertensive drug class over another with respect to improving BP control or altering cardiovascular outcomes; accordingly, selection of the appropriate antihypertensive regimen should be individualized. To individualize therapy, consideration should be given to intra- and interdialytic pharmacokinetics, effect on cardiovascular reflexes, ability to treat comorbid illnesses, and adverse effect profile.\n                    <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                    -Blockers followed by dihydropyridine calcium-channel blockers are our first- and second-line choices for antihypertensive drug use. Angiotensin\u2013converting enzyme inhibitors and angiotensin receptor blockers seem to be reasonable third\u2013line choices, because the evidence base to support their use in patients on dialysis is sparse. Add-on therapy with mineralocorticoid receptor antagonists in specific subgroups of patients on dialysis (\n                    <jats:italic toggle=\"yes\">i.e.<\/jats:italic>\n                    , those with severe congestive heart failure) seems to be another promising option in anticipation of the ongoing trials evaluating their efficacy and safety. Adequately powered, multicenter, randomized trials evaluating hard cardiovascular end points are urgently warranted to elucidate the comparative effectiveness of antihypertensive drug classes in patients on dialysis. In this review, we provide an overview of the randomized evidence on pharmacotherapy of hypertension in patients on dialysis, and we conclude with suggestions for future research to address critical gaps in this important area.\n                  <\/jats:p>","DOI":"10.2215\/cjn.00870116","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T22:29:33Z","timestamp":1477348173000},"page":"2062-2075","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacotherapy of Hypertension in Chronic Dialysis Patients"],"prefix":"10.2215","volume":"11","author":[{"given":"Panagiotis I.","family":"Georgianos","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, First Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis, Indianapolis; and"},{"name":"Division of Nephrology, Department of Medicine, Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(03)00366-8","article-title":"Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States","volume":"115","author":"Agarwal","year":"2003","journal-title":"Am J Med"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000331067","article-title":"Epidemiology of interdialytic ambulatory hypertension and the role of volume excess","volume":"34","author":"Agarwal","year":"2011","journal-title":"Am J Nephrol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/HYPERTENSIONAHA.109.144899","article-title":"Blood pressure and mortality among hemodialysis patients","volume":"55","author":"Agarwal","year":"2010","journal-title":"Hypertension"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1681\/ASN.2013060601","article-title":"Assessment and management of hypertension in patients on dialysis","volume":"25","author":"Agarwal","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/ki.2009.469","article-title":"Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference","volume":"77","author":"Levin","year":"2010","journal-title":"Kidney Int"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/ndt\/gfs597","article-title":"Shorter delivered dialysis times associate with a higher and more difficult to treat blood pressure","volume":"28","author":"Tandon","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2215\/CJN.01760210","article-title":"Dry-weight: A concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients","volume":"5","author":"Agarwal","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2215\/CJN.00110108","article-title":"Age-related blood pressure patterns and blood pressure variability among hemodialysis patients","volume":"3","author":"Rohrscheib","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2215\/CJN.01891105","article-title":"Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure","volume":"1","author":"Agarwal","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.2215\/CJN.02250507","article-title":"Home blood pressures are of greater prognostic value than hemodialysis unit recordings","volume":"2","author":"Alborzi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1046\/j.1523-1755.2000.00107.x","article-title":"Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients","volume":"57","author":"Amar","year":"2000","journal-title":"Kidney Int"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1523-1755.1998.00853.x","article-title":"Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients","volume":"53","author":"Zoccali","year":"1998","journal-title":"Kidney Int"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1159\/000252775","article-title":"Prognostic value of circadian blood pressure variation in chronic kidney disease","volume":"30","author":"Agarwal","year":"2009","journal-title":"Am J Nephrol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.108.125674","article-title":"Dry-weight reduction in hypertensive hemodialysis patients (DRIP): A randomized, controlled trial","volume":"53","author":"Agarwal","year":"2009","journal-title":"Hypertension"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: A randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/HYPERTENSIONAHA.108.128116","article-title":"Cardiovascular protection with antihypertensive drugs in dialysis patients: Systematic review and meta-analysis","volume":"53","author":"Agarwal","year":"2009","journal-title":"Hypertension"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","article-title":"Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: A systematic review and meta-analysis of randomised controlled trials","volume":"373","author":"Heerspink","year":"2009","journal-title":"Lancet"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/ndt\/gfm805","article-title":"Acute effects of low and high intravenous doses of furosemide on myocardial function in anuric haemodialysis patients: A tissue Doppler study","volume":"23","author":"Hayashi","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s10157-011-0427-z","article-title":"Use of small doses of furosemide in chronic kidney disease patients with residual renal function undergoing hemodialysis","volume":"15","author":"Lemes","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study","volume":"21","author":"Takahashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: An open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2215\/CJN.07831109","article-title":"Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: A meta-analysis","volume":"5","author":"Tai","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","article-title":"Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: A randomized controlled trial","volume":"28","author":"Iseki","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/15701611113119990147","article-title":"Arterial stiffness: A novel cardiovascular risk factor in kidney disease patients","volume":"13","author":"Georgianos","year":"2015","journal-title":"Curr Vasc Pharmacol"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1523-1755.2004.00530.x","article-title":"Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression","volume":"65","author":"Zoccali","year":"2004","journal-title":"Kidney Int"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.atherosclerosis.2009.04.005","article-title":"Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis","volume":"207","author":"Mitsuhashi","year":"2009","journal-title":"Atherosclerosis"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.ajkd.2005.11.024","article-title":"Effect of ramipril on left ventricular mass in normotensive hemodialysis patients","volume":"47","author":"Yu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e318249d387","article-title":"Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: A meta-analysis","volume":"345","author":"Yang","year":"2013","journal-title":"Am J Med Sci"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ki.2014.69","article-title":"No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients","volume":"86","author":"Peters","year":"2014","journal-title":"Kidney Int"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ki.2014.155","article-title":"Pleiotropic effects of angiotensin II blockers in hemodialysis patients: Myth or reality?","volume":"86","author":"Zoccali","year":"2014","journal-title":"Kidney Int"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1525-139X.2009.00697.x","article-title":"Antihypertensive agents in hemodialysis patients: A current perspective","volume":"23","author":"Inrig","year":"2010","journal-title":"Semin Dial"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.2215\/CJN.12371214","article-title":"The safety of eplerenone in hemodialysis patients: A noninferiority randomized controlled trial","volume":"10","author":"Walsh","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.ajkd.2015.09.029","article-title":"New potassium binders: A call to test their efficacy and safety in dialysis patients","volume":"67","author":"Georgianos","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term effects of spironolactone in peritoneal dialysis patients","volume":"25","author":"Ito","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jch.12374","article-title":"Effects of spironolactone on dialysis patients with refractory hypertension: A randomized controlled study","volume":"16","author":"Ni","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-term effects of low-dose spironolactone on chronic dialysis patients: A randomized placebo-controlled study","volume":"18","author":"Lin","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1525-139X.2007.00367.x","article-title":"Beta-blockade in chronic dialysis patients","volume":"21","author":"Furgeson","year":"2008","journal-title":"Semin Dial"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2215\/CJN.09981014","article-title":"Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis","volume":"10","author":"Georgianos","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.ajkd.2015.10.029","article-title":"The \u03b2-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A randomized controlled trial","volume":"67","author":"Roberts","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1681\/ASN.2014040324","article-title":"\u03b2-Blocker dialyzability and mortality in older patients receiving hemodialysis","volume":"26","author":"Weir","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000058396","article-title":"Nonselective Beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients","volume":"91","author":"Nowicki","year":"2002","journal-title":"Nephron"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/HJH.0b013e3280104fa5","article-title":"Metabolic effects of beta-blockers: Importance of dissociating newer from conventional agents","volume":"25","author":"Sarafidis","year":"2007","journal-title":"J Hypertens"},{"key":"B50-20230813","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1161\/01.CIR.82.1.105","article-title":"Salt and water retention and calcium blockade in uremia","volume":"82","author":"London","year":"1990","journal-title":"Circulation"},{"key":"B51-20230813","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","article-title":"Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients","volume":"23","author":"Tepel","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B52-20230813","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/sj.ki.5001983","article-title":"Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis","volume":"70","author":"Aslam","year":"2006","journal-title":"Kidney Int"},{"key":"B53-20230813","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3109\/0886022X.2010.502276","article-title":"Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"32","author":"Yilmaz","year":"2010","journal-title":"Ren Fail"},{"key":"B54-20230813","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/jch.12718","article-title":"Mineralocorticoid receptor antagonism for cardiovascular protection in end-stage renal disease: New data but the controversy continues","volume":"18","author":"Georgianos","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B55-20230813","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.11041210","article-title":"Intradialytic hypertension and the association with interdialytic ambulatory blood pressure","volume":"6","author":"Van Buren","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B56-20230813","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/HYPERTENSIONAHA.115.05858","article-title":"Intradialysis hypertension in end-stage renal disease patients: Clinical epidemiology, pathogenesis, and treatment","volume":"66","author":"Georgianos","year":"2015","journal-title":"Hypertension"},{"key":"B57-20230813","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1093\/ndt\/gfq210","article-title":"Intradialytic hypertension is a marker of volume excess","volume":"25","author":"Agarwal","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B58-20230813","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2215\/CJN.10010911","article-title":"Probing the mechanisms of intradialytic hypertension: A pilot study targeting endothelial cell dysfunction","volume":"7","author":"Inrig","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B59-20230813","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1046\/j.1523-1755.1999.00359.x","article-title":"Supervised atenolol therapy in the management of hemodialysis hypertension","volume":"55","author":"Agarwal","year":"1999","journal-title":"Kidney Int"},{"key":"B60-20230813","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1053\/ajkd.2001.29221","article-title":"Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses","volume":"38","author":"Agarwal","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B61-20230813","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1093\/ndt\/gfp332","article-title":"Home blood pressure monitoring in blood pressure control among haemodialysis patients: An open randomized clinical trial","volume":"24","author":"da Silva","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B62-20230813","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/039139880202500404","article-title":"Long-term control of hypertension in dialysis patients by low dose atenolol","volume":"25","author":"Vlassopoulos","year":"2002","journal-title":"Int J Artif Organs"},{"key":"B63-20230813","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1291\/hypres.28.987","article-title":"Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients","volume":"28","author":"Shimada","year":"2005","journal-title":"Hypertens Res"},{"key":"B64-20230813","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000107490","article-title":"ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients","volume":"27","author":"Zheng","year":"2007","journal-title":"Am J Nephrol"},{"key":"B65-20230813","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1161\/01.CIR.90.6.2786","article-title":"Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade","volume":"90","author":"London","year":"1994","journal-title":"Circulation"},{"key":"B66-20230813","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000049060","article-title":"Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease","volume":"90","author":"Shibasaki","year":"2002","journal-title":"Nephron"},{"key":"B67-20230813","first-page":"59","article-title":"A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness","volume":"19","author":"Suzuki","year":"2003","journal-title":"Adv Perit Dial"},{"key":"B68-20230813","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1526-0968.2004.00142.x","article-title":"Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy","volume":"8","author":"Suzuki","year":"2004","journal-title":"Ther Apher Dial"},{"key":"B69-20230813","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00005344-200403000-00008","article-title":"Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients","volume":"43","author":"Kanno","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"B70-20230813","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/j.ajkd.2005.02.022","article-title":"Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients","volume":"45","author":"Ichihara","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B71-20230813","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1291\/hypres.29.253","article-title":"Effects of imidapril on left ventricular mass in chronic hemodialysis patients","volume":"29","author":"Matsumoto","year":"2006","journal-title":"Hypertens Res"},{"key":"B72-20230813","doi-asserted-by":"crossref","first-page":"c31","DOI":"10.1159\/000210572","article-title":"Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis","volume":"112","author":"Shigenaga","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"B73-20230813","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B74-20230813","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B75-20230813","first-page":"507","article-title":"A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B76-20230813","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1753944715591448","article-title":"Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients","volume":"9","author":"Feniman-De-Stefano","year":"2015","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"B77-20230813","doi-asserted-by":"crossref","first-page":"c49","DOI":"10.1159\/000078400","article-title":"Antihypertensive effects of long-acting calcium channel blockers on hemodialysis days--a randomized crossover trial between benidipine and nifedipine CR","volume":"97","author":"Kojima","year":"2004","journal-title":"Nephron Clin Pract"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201611000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:46:57Z","timestamp":1786369617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201611000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.00870116","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]}}}